TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32750502

Group type: EXPERIMENTAL
Intervention: Upfront combination therapy with fluoropyrimidine (FP), irinotecan (Iri), and bevacizumab (Bev)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Sequential treatment with FP and Bev followed by escalation to Iri, FP, and Bev
Number of subjects: 421
Study: 35180284

Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake (median 194.4 μg/d)
Number of subjects: 5533

Group type: COMPARATOR
Intervention: Decrease in dietary vitamin K intake (median -97.8 μg/d)
Number of subjects: 5533

Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake
Number of subjects: 5533
Study: 34817971

Group type: EXPERIMENTAL
Intervention: Cariestop (Biodinamica Quimica y Farmaceutica)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: RivaStar 1 (SDI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: RivaStar 2 (SDI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Saforide (Tokyo Seiyaku Kasei)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Demineralized dentin (positive control)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sound dentin (negative control)
Number of subjects: 90
Study: 36087070

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study: 34397500

Group type: EXPERIMENTAL
Intervention: Therapeutic conversation with an ED nurse
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 166
Study: 32479645

Group type: EXPERIMENTAL
Intervention: Brief psychological intervention targeting fear of recurrence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine care implementation
Number of subjects: 0
Study: 35653145

Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg, twice daily) plus endocrine therapy (ET) for 2 years
Number of subjects: 5637

Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 5637
Study: 32554173

Group type: EXPERIMENTAL
Intervention: Web-version of Prolonged Exposure (Web-PE) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) delivered in-person as part of an intensive outpatient PTSD program
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person Present-Centered Therapy (PCT)
Number of subjects: 0
Study: 35910936

Group type: EXPERIMENTAL
Intervention: Family-Centered Empowerment Model (FCEM)
Number of subjects: 70
Study: 34992553

Group type: EXPERIMENTAL
Intervention: Music therapy conducted by trained music therapists
Number of subjects: 57

Group type: COMPARATOR
Intervention: Music listening together with a social care worker
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both interventions (Music therapy and Music listening)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Music therapy and Music listening
Number of subjects: 57
Study: 32067251

Group type: EXPERIMENTAL
Intervention: Refugee Well‐being Project (RWP) intervention, a 6-month multilevel, strengths‐based program involving university students and refugees.
Number of subjects: 290
Study: 36473717

Group type: EXPERIMENTAL
Intervention: Lavandula essential oil (LEO) - 5 drops of 20% LEO inhaled for three consecutive days, intervention performed every 24 hours.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo - 5 drops of distilled water inhaled for three consecutive days, intervention performed every 24 hours.
Number of subjects: 98
Study: 33165310

Group type: EXPERIMENTAL
Intervention: Trunk training (N=19)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cognitive training (N=20)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Trunk training
Number of subjects: 45
Study: 32042108

Group type: EXPERIMENTAL
Intervention: Morning classes (07:45)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Afternoon classes (12:40)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Evening classes (17:20)
Number of subjects: 753
Study: 35633027

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg bid (starting dose 500 mg) for 12 weeks
Number of subjects: 50
Study: 34289514

Group type: EXPERIMENTAL
Intervention: Standard conservative management plus acupuncture (6 sessions over 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard conservative management for OAB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard conservative management plus acupuncture
Number of subjects: 30
Study: 32711802

Group type: EXPERIMENTAL
Intervention: Continued prednisone 5 mg per day for 24 weeks
Number of subjects: 259

Group type: COMPARATOR
Intervention: Tapered prednisone reaching 0 mg per day at week 16
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 259

Group type: COMPARATOR
Intervention: Tapered prednisone
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Continued prednisone
Number of subjects: 259
Study: 35667659

Group type: EXPERIMENTAL
Intervention: Inulin-type fructan intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34547064

Group type: EXPERIMENTAL
Intervention: Crown lengthening and tooth reconstruction (experimental group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Extraction and replacement (control group)
Number of subjects: 126
Study: 36134818

Group type: EXPERIMENTAL
Intervention: Appendicitis Inflammatory Response score flowchart
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine clinical-radiological diagnosis
Number of subjects: 110
Study: 35476136

Group type: EXPERIMENTAL
Intervention: Rehabilitative exercises (treadmill running, lower extremity strengthening exercises, plyometric exercises) for 30 minutes each
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plyometric loading
Number of subjects: 12
Study: 32298662

Group type: EXPERIMENTAL
Intervention: MEP+ group (presence of MEPs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MEP- group (absence of MEPs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 28
Study: 35351020

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood mononuclear cells (UCB-MNCs) administered via intrathecal route (5 × 10^6 /kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (sham treatment)
Number of subjects: 72
Study: 33954853

Group type: EXPERIMENTAL
Intervention: Usual care + intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 31
Study: 32621735

Group type: EXPERIMENTAL
Intervention: Expert advice on therapeutic exercise
Number of subjects: 500

Group type: COMPARATOR
Intervention: Normal lifestyle (control group)
Number of subjects: 500
Study: 36208780

Group type: EXPERIMENTAL
Intervention: Moderate green space VR exposure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High green space VR exposure
Number of subjects: 63
Study: 33964099

Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 54
Study: 32860117

Group type: EXPERIMENTAL
Intervention: Frequent short bouts of physical activity (FPA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sitting (SIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate-intensity exercise (EXE)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baseline to 5 min post-PAS
Number of subjects: 16
Study: 36435926

Group type: EXPERIMENTAL
Intervention: Spiritual care program (4 sessions of 45-60 min each, one session per week)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 108
Study: 34880055

Group type: EXPERIMENTAL
Intervention: Proactive, standardised, nurse led telephone management of common toxicities
Number of subjects: 2158

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 2158
Study: 35930800

Group type: EXPERIMENTAL
Intervention: Menstruation phase
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Late luteal phase
Number of subjects: 17

Group type: COMPARATOR
Intervention: Menstruation, mid-follicular, and late luteal phases
Number of subjects: 17
Study: 35115225

Group type: EXPERIMENTAL
Intervention: Midpoint transverse process-to-pleura block (MTPB)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 81
Study: 36099251

Group type: EXPERIMENTAL
Intervention: Small-Sided Games (SSG) training group (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simulated Match Handball Training (SMHT) group (n = 12)
Number of subjects: 24
Study: 34099403

Group type: EXPERIMENTAL
Intervention: Autologous bio‐regenerative fibrin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traditional methods of hemostasis
Number of subjects: 74
Study: 32766883

Group type: EXPERIMENTAL
Intervention: Postdischarge thrombosis (including arterial and venous events)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Postdischarge venous thromboembolism
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Postdischarge major hemorrhage
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Postdischarge clinically relevant nonmajor bleeds
Number of subjects: 163
Study: 34661691

Group type: EXPERIMENTAL
Intervention: CEX-p-FAST
Number of subjects: 296

Group type: COMPARATOR
Intervention: CEX-only
Number of subjects: 296
Study: 34016436

Group type: EXPERIMENTAL
Intervention: OnTrack application for medication management
Number of subjects: 153

Group type: COMPARATOR
Intervention: Conventional medication management
Number of subjects: 153
Study: 33361075

Group type: EXPERIMENTAL
Intervention: Real dry cupping
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham dry cupping
Number of subjects: 62
Study: 35486613

Group type: EXPERIMENTAL
Intervention: ASC (2.8 million ASCs/cm3 injection)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ASC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32868497

Group type: EXPERIMENTAL
Intervention: WHO modified checklist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHO checklist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (no checklist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All checklist groups
Number of subjects: 0
Study: 35152576

Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding therapy with PGLA thread applied to acupoints (Tianshu, Zhongwan, Ganshu, Shuidao) once every 2 weeks for 12 weeks.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham-embedding group (same acupoint selection and operation without PGLA thread).
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding therapy with PGLA thread.
Number of subjects: 144
Study: 33125518

Group type: EXPERIMENTAL
Intervention: SRP+PLGA/PLA nanoparticles loaded with 50 μg of curcumin (N‐Curc)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP+empty nanoparticles (Control)
Number of subjects: 20
Study: 36429423

Group type: EXPERIMENTAL
Intervention: Intervention A (patient messaging intervention)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Intervention B (patient messaging intervention plus online education)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 420
Study: 34191812

Group type: EXPERIMENTAL
Intervention: Ivermectin-albendazole
Number of subjects: 2050

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 2050
Study: 32271377

Group type: EXPERIMENTAL
Intervention: Durvalumab (20 mg/kg every 4 weeks)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (20 mg/kg durvalumab + 1 mg/kg tremelimumab every 4 weeks, up to 4 doses)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based doublet)
Number of subjects: 1118
Study: 36138361

Group type: EXPERIMENTAL
Intervention: 5A based self‐management program for 6 weeks (in‐person and off‐site)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine care includes stroke training booklets and post‐discharge care training by the ward nurse
Number of subjects: 72
Study: 35223393

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg; 30 minutes before bedtime) for 2 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg; 30 minutes before bedtime)
Number of subjects: 110
Study: 34881919

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 32770384

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRHant) alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRHant) with estradiol add‐back
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vitamin C (antioxidant) infusion
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRHant) + placebo
Number of subjects: 87

Group type: COMPARATOR
Intervention: GnRH antagonist (GnRHant) + estradiol
Number of subjects: 87
Study: 35987829

Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Technical Assistance (TA)
Number of subjects: 55
Study: 34148124

Group type: EXPERIMENTAL
Intervention: Heat acclimation (HA) training for 5 days at 34.9 ± 0.7 °C, 53 ± 4% relative humidity
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON) training for 5 days at 22.2 ± 2.6 °C, 65 ± 8% relative humidity
Number of subjects: 8
Study: 35561963

Group type: EXPERIMENTAL
Intervention: Active TNS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham TNS
Number of subjects: 20
Study: 34039938

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale (GCS) score
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Documented acute mental status
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: GCS score documentation
Number of subjects: 773
Study: 36191643

Group type: EXPERIMENTAL
Intervention: Brexanolone 90 μg/kg/h (BRX90)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 33315355

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin
Number of subjects: 68
Study: 32025830

Group type: EXPERIMENTAL
Intervention: 3rd-generation DSCT
Number of subjects: 575
Study: 616484288

Group type: EXPERIMENTAL
Intervention: Standard doses of H1‐AHs
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 2nd line treatments (combining or updosing AHs)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Omalizumab as a 3rd line treatment
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Continuing omalizumab treatment for 24 weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: 2nd line treatments
Number of subjects: 136
Study: 34376546

Group type: EXPERIMENTAL
Intervention: Alternating seated-standing protocol (training group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no alternating seated-standing protocol)
Number of subjects: 30
Study: 33258890

Group type: EXPERIMENTAL
Intervention: THC-dominant cannabis (13.75 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: THC/CBD-equivalent cannabis (13.75 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CBD-dominant cannabis (13.75 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 26
Study: 37453240

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temozolomide (TMZ) + Bevacizumab (BEV)
Number of subjects: 0
Study: 34459214

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 545

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 545
Study: 32184198

Group type: EXPERIMENTAL
Intervention: Written exposure therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Imaginal exposure
Number of subjects: 300
Study: 36054624

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0

Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 0
Study: 32804837

Group type: EXPERIMENTAL
Intervention: Allicin-containing quadruple therapy (IDFA)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (IDFB)
Number of subjects: 220
Study: 36172933

Group type: COMPARATOR
Intervention: LDL-C 70 to 100 mg/dL
Number of subjects: 8500

Group type: COMPARATOR
Intervention: LDL-C <70 mg/dL
Number of subjects: 8500
Study: 33612359

Group type: EXPERIMENTAL
Intervention: AP overlay with Gel pad
Number of subjects: 180

Group type: COMPARATOR
Intervention: Gel pad
Number of subjects: 180
Study: 32314781

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate (CEE+MPA)
Number of subjects: 40
Study: 34788822

Group type: EXPERIMENTAL
Intervention: FA-containing B vitamins
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study: 34145336

Group type: EXPERIMENTAL
Intervention: gemcitabine plus S‐1 (GS)
Number of subjects: 354

Group type: COMPARATOR
Intervention: gemcitabine plus cisplatin (GC)
Number of subjects: 354
Study: 32135381

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus and Lactobacillus johnsonii)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 34757487

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Weight loss ≥ 5%
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 1767
Study: 34083576

Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 0.02% atropine
Number of subjects: 328
Study: 35328926

Group type: EXPERIMENTAL
Intervention: Electronic Cigarette (EC) smoking
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tobacco Cigarette (TC) smoking
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 12
Study: 33167952

Group type: COMPARATOR
Intervention: Balint groups
Number of subjects: 362

Group type: COMPARATOR
Intervention: Narrative medicine training
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 362
Study: 36155119

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg/day for 90 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 33285347

Group type: EXPERIMENTAL
Intervention: Evidence-based therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lower delusional distress at discharge
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Black and Minority Ethnic (BME) background
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Discharged to an Early Intervention (EI) service
Number of subjects: 48
Study: 33027506

Group type: EXPERIMENTAL
Intervention: Economic Threat condition
Number of subjects: 103

Group type: COMPARATOR
Intervention: No-Threat Control condition
Number of subjects: 103
Study: 35331015

Group type: EXPERIMENTAL
Intervention: Fab antivenom
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32331016

Group type: EXPERIMENTAL
Intervention: Lurasidone (20-80 mg/d)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo (switched to lurasidone)
Number of subjects: 306
Study: 34539185

Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg loading dose, followed by 0.5 mg b.i.d. for one week and 0.5 mg per day for 28 days)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Colchicine and Standard treatment
Number of subjects: 103
Study: 32678713

Group type: EXPERIMENTAL
Intervention: Group A: PBM with power 250 mW, energy density 8.8 J/cm2 for WHO grade 3 and 15.5 J/cm2 for WHO grade 4.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B: PBM with power 500 mW, energy density as in group A.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group C: PBM with power 250 mW, energy density was half of groups A and B.
Number of subjects: 0
Study: 34296544

Group type: EXPERIMENTAL
Intervention: GEMOX-T (gemcitabine 1000 mg/m² and oxaliplatin 50 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: GT (gemcitabine 1000 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GEMOX-T
Number of subjects: 65

Group type: COMPARATOR
Intervention: GT
Number of subjects: 65
Study: 33009572

Group type: EXPERIMENTAL
Intervention: Type 33 phage vector with optimized copy number of peptides displayed on the phage surface.
Number of subjects: 0
Study: 35881893

Group type: COMPARATOR
Intervention: Oral sildenafil (0.5‐2 mg/kg/6 hours)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (0.25‐0.75 mic/kg/min)
Number of subjects: 40
Study: 34887636

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram integrating radiomics score and clinical factors
Number of subjects: 118

Group type: COMPARATOR
Intervention: Radiomics score or only clinical factors (comparison to the nomogram)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: High-risk stratification based on the nomogram
Number of subjects: 118
Study: 33028102

Group type: EXPERIMENTAL
Intervention: Xyloglucan/gelose plus ORS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus ORS
Number of subjects: 50
Study: 32317829

Group type: EXPERIMENTAL
Intervention: Self-reported respiratory symptoms and asthma medication use among adolescents
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Gender comparison in respiratory symptoms
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Frequency of wheezing attacks
Number of subjects: 1200
Study: 34303265

Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg
Number of subjects: 2176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 2176
Study: 32187913

Group type: EXPERIMENTAL
Intervention: Optimal feature subset prediction model using Fisher-NDA
Number of subjects: 144
Study: 35510376

Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB)
Number of subjects: 2413
Study: 34337072

Group type: EXPERIMENTAL
Intervention: Insulin titration goal of FBG≤6.1 mmol/L
Number of subjects: 71

Group type: COMPARATOR
Intervention: Insulin titration goal of FBG≤5.6 mmol/L
Number of subjects: 71

Group type: COMPARATOR
Intervention: Insulin titration goal of FBG≤7.0 mmol/L
Number of subjects: 71